Skip to main content
A

AbClon Inc. — Investor Relations & Filings

Ticker · 174900 ISIN · KR7174900001 KO Manufacturing
Open in API
Filings indexed 252 across all filing types
Latest filing 2025-05-09 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 174900

About AbClon Inc.

https://www.abclon.com/en/

AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from AbClon Inc. regarding a decision for a third-party paid-in capital increase (유상증자결정). It details the issuance of new shares, the purpose of the funds (operating capital for R&D), the target entity (Chong Kun Dang), and the specific terms of the capital increase. This falls under the category of share issuance and capital changes.
2025-05-09 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from a Korean company (AbClon) titled 'Audit Report Submission' (감사보고서 제출). It provides a correction (정정신고) to a previously filed audit report, detailing specific changes to financial figures (assets, liabilities, revenue, etc.) and explicitly mentioning 're-audit' (재감사) as the reason for the correction. Since this is a formal regulatory disclosure of audit-related financial data rather than the full audit report document itself, it falls under the category of Audit Report / Information. FY 2024
2025-04-28 Korean
[기재정정]사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for AbClon Inc. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity), and notes to the financial statements. It specifically mentions a correction ('정정') of a previously issued audit report due to accounting errors in revenue recognition. As it is a standalone audit report and not a full 10-K annual report, it falls under the Audit Report category. FY 2023
2025-04-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when a major shareholder's stake changes. It details the shareholding status of the CEO (Lee Jong-seo) and related parties in the company 'AbClon'. This falls under the category of Major Shareholding Notification (MRQ).
2025-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'AbClon'. It details the approval of financial statements, director appointments, and other agenda items voted upon during the meeting held on March 31, 2025. This falls directly under the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to executives and employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for personal trades) or SHA (which is for general share issuance).
2025-03-31 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.